SEAGEN INC (SGEN) Fundamental Analysis & Valuation
NASDAQ:SGEN • US81181C1045
Current stock price
228.74 USD
-0.16 (-0.07%)
At close:
228.95 USD
+0.21 (+0.09%)
After Hours:
This SGEN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. SGEN Profitability Analysis
1.1 Basic Checks
- In the past year SGEN has reported negative net income.
- SGEN had a negative operating cash flow in the past year.
1.2 Ratios
- SGEN's Return On Assets of -20.64% is amongst the best of the industry. SGEN outperforms 82.06% of its industry peers.
- The Return On Equity of SGEN (-29.41%) is better than 81.40% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -20.64% | ||
| ROE | -29.41% | ||
| ROIC | N/A |
ROA(3y)-6.47%
ROA(5y)-8.28%
ROE(3y)-8.73%
ROE(5y)-10.42%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- Looking at the Gross Margin, with a value of 75.39%, SGEN belongs to the top of the industry, outperforming 84.88% of the companies in the same industry.
- In the last couple of years the Gross Margin of SGEN has declined.
- The Profit Margin and Operating Margin are not available for SGEN so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 75.39% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.99%
GM growth 5Y-2.28%
2. SGEN Health Analysis
2.1 Basic Checks
- SGEN does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, SGEN has more shares outstanding
- SGEN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- SGEN has an Altman-Z score of 23.31. This indicates that SGEN is financially healthy and has little risk of bankruptcy at the moment.
- With an excellent Altman-Z score value of 23.31, SGEN belongs to the best of the industry, outperforming 94.68% of the companies in the same industry.
- There is no outstanding debt for SGEN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 23.31 |
ROIC/WACCN/A
WACC10.94%
2.3 Liquidity
- SGEN has a Current Ratio of 2.67. This indicates that SGEN is financially healthy and has no problem in meeting its short term obligations.
- SGEN's Current ratio of 2.67 is on the low side compared to the rest of the industry. SGEN is outperformed by 73.26% of its industry peers.
- SGEN has a Quick Ratio of 2.12. This indicates that SGEN is financially healthy and has no problem in meeting its short term obligations.
- Looking at the Quick ratio, with a value of 2.12, SGEN is doing worse than 76.91% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.67 | ||
| Quick Ratio | 2.12 |
3. SGEN Growth Analysis
3.1 Past
- SGEN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -16.23%.
- The Revenue has grown by 23.40% in the past year. This is a very strong growth!
- SGEN shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 32.40% yearly.
EPS 1Y (TTM)-16.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.65%
Revenue 1Y (TTM)23.4%
Revenue growth 3Y28.88%
Revenue growth 5Y32.4%
Sales Q2Q%27.12%
3.2 Future
- SGEN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 32.31% yearly.
- SGEN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 26.49% yearly.
EPS Next Y-28.74%
EPS Next 2Y17.92%
EPS Next 3Y29.83%
EPS Next 5Y32.31%
Revenue Next Year28.4%
Revenue Next 2Y30.41%
Revenue Next 3Y29.91%
Revenue Next 5Y26.49%
3.3 Evolution
- The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. SGEN Valuation Analysis
4.1 Price/Earnings Ratio
- SGEN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SGEN. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as SGEN's earnings are expected to grow with 29.83% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.92%
EPS Next 3Y29.83%
5. SGEN Dividend Analysis
5.1 Amount
- SGEN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SGEN Fundamentals: All Metrics, Ratios and Statistics
228.74
-0.16 (-0.07%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-01 2023-11-01/bmo
Earnings (Next)02-13 2024-02-13/amc
Inst Owners0.21%
Inst Owner Change0%
Ins Owners0.86%
Ins Owner Change0%
Market Cap43.15B
Revenue(TTM)2.30B
Net Income(TTM)-750.20M
Analysts72.17
Price Target233.48 (2.07%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-39.9%
Min EPS beat(2)-42.41%
Max EPS beat(2)-37.4%
EPS beat(4)1
Avg EPS beat(4)-16.67%
Min EPS beat(4)-42.41%
Max EPS beat(4)24.39%
EPS beat(8)3
Avg EPS beat(8)-5.14%
EPS beat(12)5
Avg EPS beat(12)-16.24%
EPS beat(16)8
Avg EPS beat(16)36.61%
Revenue beat(2)2
Avg Revenue beat(2)2.94%
Min Revenue beat(2)0.14%
Max Revenue beat(2)5.73%
Revenue beat(4)3
Avg Revenue beat(4)3.09%
Min Revenue beat(4)-1.45%
Max Revenue beat(4)7.95%
Revenue beat(8)7
Avg Revenue beat(8)5.12%
Revenue beat(12)10
Avg Revenue beat(12)4.52%
Revenue beat(16)14
Avg Revenue beat(16)12.68%
PT rev (1m)0%
PT rev (3m)1.81%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-47.4%
EPS NY rev (1m)-17.92%
EPS NY rev (3m)-19.95%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)101391%
Revenue NY rev (1m)0.8%
Revenue NY rev (3m)0.85%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 18.76 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 16.92 | ||
| P/tB | 20.99 | ||
| EV/EBITDA | N/A |
EPS(TTM)-4.01
EYN/A
EPS(NY)-2.01
Fwd EYN/A
FCF(TTM)-3.72
FCFYN/A
OCF(TTM)-2.86
OCFYN/A
SpS12.19
BVpS13.52
TBVpS10.9
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -20.64% | ||
| ROE | -29.41% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 75.39% | ||
| FCFM | N/A |
ROA(3y)-6.47%
ROA(5y)-8.28%
ROE(3y)-8.73%
ROE(5y)-10.42%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.99%
GM growth 5Y-2.28%
F-Score3
Asset Turnover0.63
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 219.65% | ||
| Cap/Sales | 7% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.67 | ||
| Quick Ratio | 2.12 | ||
| Altman-Z | 23.31 |
F-Score3
WACC10.94%
ROIC/WACCN/A
Cap/Depr(3y)115.85%
Cap/Depr(5y)145.31%
Cap/Sales(3y)3.68%
Cap/Sales(5y)4.4%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-16.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.65%
EPS Next Y-28.74%
EPS Next 2Y17.92%
EPS Next 3Y29.83%
EPS Next 5Y32.31%
Revenue 1Y (TTM)23.4%
Revenue growth 3Y28.88%
Revenue growth 5Y32.4%
Sales Q2Q%27.12%
Revenue Next Year28.4%
Revenue Next 2Y30.41%
Revenue Next 3Y29.91%
Revenue Next 5Y26.49%
EBIT growth 1Y-18.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-16.02%
EBIT Next 3Y33.65%
EBIT Next 5Y31.94%
FCF growth 1Y-758.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1946.21%
OCF growth 3YN/A
OCF growth 5YN/A
SEAGEN INC / SGEN Fundamental Analysis FAQ
What is the ChartMill fundamental rating of SEAGEN INC (SGEN) stock?
ChartMill assigns a fundamental rating of 4 / 10 to SGEN.
What is the valuation status for SGEN stock?
ChartMill assigns a valuation rating of 1 / 10 to SEAGEN INC (SGEN). This can be considered as Overvalued.
What is the profitability of SGEN stock?
SEAGEN INC (SGEN) has a profitability rating of 2 / 10.
How financially healthy is SEAGEN INC?
The financial health rating of SEAGEN INC (SGEN) is 7 / 10.